Dynavax Technologies CorpNASDAQ:DVAX
- LAST PRICE10.9850
- TODAY'S CHANGE (%)-0.2250 (-2.0071%)
- Bid / Lots10.9800/ 5
- Ask / Lots10.9900/ 3
- Open / Previous Close11.1300 / 11.2100
- Day Range
- 52 Week Range
- Volume132,031
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | DVAX |
|---|---|---|
| 09:32 ET | 15847 | 11.045 |
| 09:34 ET | 51264 | 11 |
| 09:36 ET | 2477 | 10.96 |
| 09:38 ET | 2905 | 10.985 |
| 09:39 ET | 200 | 11.0299 |
| 09:43 ET | 699 | 11.05 |
| 09:45 ET | 100 | 11.03 |
| 09:48 ET | 900 | 11.045 |
| 09:50 ET | 3200 | 11.035 |
| 09:52 ET | 1900 | 11.05 |
| 09:54 ET | 2100 | 11.04 |
| 09:56 ET | 908 | 11.045 |
| 09:57 ET | 2000 | 11.045 |
| 09:59 ET | 9863 | 11.05 |
| 10:01 ET | 1420 | 11.055 |
| 10:03 ET | 5723 | 11.01 |
| 10:06 ET | 3730 | 11.015 |
| 10:08 ET | 3267 | 10.985 |
| 10:10 ET | 2616 | 10.985 |
| 10:12 ET | 2010 | 10.985 |
May 28, 2024
Dynavax to Present at Upcoming Investor Conferences, from 4:18PM ET on Tuesday May 28, 2024 by Dow Jones
4:18PM ET on Tuesday May 28, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Dynavax Technologies Corp | 1.5B | 219.9x | --- |
MannKind Corp | 1.4B | 221.7x | --- |
Kiniksa Pharmaceuticals Ltd | 1.3B | 219.4x | --- |
Mirum Pharmaceuticals Inc | 1.6B | -8.6x | --- |
Zai Lab Ltd | 1.8B | -5.2x | --- |
Maravai LifeSciences Holdings Inc | 1.7B | -6.9x | --- |
Company Information
Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company, which is engaged in developing and commercializing vaccines. The Company's products include HEPLISAV-B hepatitis B vaccine and CpG 1018. Its HEPLISAV-B ((Recombinant)(Adjuvanted) is indicated for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. It also manufactures and sells CpG 1018 adjuvant, the adjuvant used in HEPLISAV-B. It is also engaged in developing a multi-program clinical pipeline leveraging CpG 1018 adjuvant to develop improved vaccines for indications with unmet medical needs. Its Pipeline programs include vaccine candidates under development for shingles, tetanus, diphtheria, and pertussis (Tdap) and plague. Its Shingles vaccine program Z-1018, which is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.
Contact Information
- Headquarters
- 2100 Powell Street, Suite 720EMERYVILLE, CA, United States 94608
- Phone
- 510-848-5100
- Fax
- 510-848-1327
Executives
- Independent Chairman of the Board
- Scott Myers
- President, Chief Operating Officer
- David Novack
- Chief Executive Officer, Director
- Ryan Spencer
- Senior Vice President, General Counsel
- John Slebir
- Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs
- Robert Janssen
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.5B |
|---|---|
Revenue (TTM) | $236.1M |
Shares Outstanding | 130.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.27 |
EPS | $0.05 |
Book Value | $4.80 |
P/E Ratio | 219.9x |
Price/Sales (TTM) | 6.2 |
Price/Cash Flow (TTM) | 107.3x |
Operating Margin | -10.40% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
